- Home
- DAWN vs BGB Comparison
DAWN vs BGB Comparison
Compare DAWN & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- BGB
- Stock Information
- Founded
- DAWN 2018
- BGB 2012
- Country
- DAWN United States
- BGB United States
- Employees
- DAWN N/A
- BGB N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- BGB Trusts Except Educational Religious and Charitable
- Sector
- DAWN Health Care
- BGB Finance
- Exchange
- DAWN Nasdaq
- BGB Nasdaq
- Market Cap
- DAWN 1.3B
- BGB N/A
- IPO Year
- DAWN 2021
- BGB N/A
- Fundamental
- Price
- DAWN $12.79
- BGB $12.29
- Analyst Decision
- DAWN Strong Buy
- BGB
- Analyst Count
- DAWN 7
- BGB 0
- Target Price
- DAWN $36.17
- BGB N/A
- AVG Volume (30 Days)
- DAWN 937.9K
- BGB 154.6K
- Earning Date
- DAWN 10-30-2024
- BGB 01-01-0001
- Dividend Yield
- DAWN N/A
- BGB 9.75%
- EPS Growth
- DAWN N/A
- BGB N/A
- EPS
- DAWN N/A
- BGB N/A
- Revenue
- DAWN $101,953,000.00
- BGB N/A
- Revenue This Year
- DAWN N/A
- BGB N/A
- Revenue Next Year
- DAWN $36.10
- BGB N/A
- P/E Ratio
- DAWN N/A
- BGB N/A
- Revenue Growth
- DAWN N/A
- BGB N/A
- 52 Week Low
- DAWN $11.94
- BGB $10.40
- 52 Week High
- DAWN $18.07
- BGB $11.97
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- BGB 40.40
- Support Level
- DAWN $12.26
- BGB $12.21
- Resistance Level
- DAWN $12.81
- BGB $12.69
- Average True Range (ATR)
- DAWN 0.52
- BGB 0.12
- MACD
- DAWN -0.05
- BGB -0.04
- Stochastic Oscillator
- DAWN 28.94
- BGB 16.67
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.